Sage Journals: Discover world-class research

Retricted access

Research article

First published 2017-12

An overview of biosimilars and non-biologic complex drugs in Europe,the United States,and Canada and their relevance to multiple sclerosis

Sophia Gran-Ruaz, Arvind Mani, Sherry O’Quinn

Multiple Sclerosis Journal

Retricted access

Research article

First published 2012-3

Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products

J. Michael Nicholas

Therapeutic Innovation & Regulatory Science

Retricted access

Review article

First published 2023-9

Regulatory framework and disparities of complex generics in United States,European Union & Latin America

Mayank Bhatt, Sampann Tank, Jignesh Shah [...]

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2026-3

Liposome drug development as complex pharmaceuticals: Current regulatory aspects in USA and EU

Alishanaz I Subedar, Fazal M. Tai

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Retricted access

Research article

First published 2016-8

The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?

Daan JA Crommelin, Karl Broich, Chris Holloway [...]

Multiple Sclerosis Journal

Retricted access

Research article

First published 2026-2

Assessment of nanomedicines and nanosimilars: Clinical pharmacists’ knowledge and regulatory gaps

Courtney Fella, Mike Isles, John Hertig

International Journal of Risk & Safety in Medicine

Retricted access

Review article

First published 2025-3

Development of complex generics: Insights into trends,challenges,and market opportunities

Rukshar Shaikh, Kajol Yadav, Kashyap Thummar [...]

Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector

Search results

An overview of biosimilars and non-biologic complex drugs in Europe,the United States,and Canada and their relevance to multiple sclerosis

Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products

Regulatory framework and disparities of complex generics in United States,European Union & Latin America

Liposome drug development as complex pharmaceuticals: Current regulatory aspects in USA and EU

The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?

Assessment of nanomedicines and nanosimilars: Clinical pharmacists’ knowledge and regulatory gaps

Development of complex generics: Insights into trends,challenges,and market opportunities